Imaging and 2‐year clinical outcomes of thin strut sirolimus‐eluting bioresorbable vascular scaffold: The MeRes‐1 extend trial. Issue 6 (2nd December 2020)

• Record Type: Journal Article
• Authors: Abizaid, Alexandre; Kedev, Sasko; Ali, Rosli Bin Mohd; Santoso, Teguh; Cequier, Angel; van Geuns, Robert‐Jan Van Geuns; Chevalier, Bernard; Hellig, Farrel; Costa, Ricardo; Onuma, Yoshinobu; Costa, Jose Ribamar; Serruys, Patrick; Bangalore, Sripal
• Is Part Of: Catheterization and cardiovascular interventions. Volume 98:Issue 6(2021)
• Page Start: 1102
• Page End: 1110
• Publication Date: 2020-12-02
• Subjects: coronary artery disease -- optical coherence tomography -- percutaneous coronary intervention -- quantitative coronary angiography -- thin‐strut scaffold; Heart -- Diseases -- Diagnosis -- Periodicals; Cardiac catheterization -- Periodicals; 616.1207572
• DOI: 10.1002/ccd.29396
• Languages: English
• ISSNs: 1522-1946

Abstract

Abstract: Objectives: This study explores the safety and efficacy of thin strut MeRes100 sirolimus‐eluting bioresorbable vascular scaffold (BRS) in patients with de novo coronary artery lesions. Background: In interventional cardiology, the emergence of BRS technology is catalyzing the next paradigm shift. Methods: The MeRes‐1 Extend was a multicenter, prospective, single‐arm, open‐label study enrolling 64 patients in Spain, Macedonia, Brazil, South Africa, Malaysia, and Indonesia. The safety endpoint was major adverse cardiac events (MACE) which composed of cardiac death, myocardial infarction (MI), and ischemia‐driven target lesion revascularization (ID‐TLR). The imaging efficacy endpoint was mean in‐scaffold late lumen loss (LLL) evaluated by quantitative coronary angiography (QCA). Optical coherence tomography (OCT) imaging was performed at baseline and 6‐month follow‐up. Results: A total of 69 target lesions were identified in 64 enrolled patients (mean age 58.30 ± 9.02 years). Of the treated lesions, 49 (71.01%) lesions were of type B2/C. Procedural and device success was achieved in 64 and 62 patients, respectively. At 2‐year follow‐up, MACE was reported in one patient (1.61%) in the form of ID‐TLR. There was no case of MI, cardiac death or scaffold thrombosis through 2‐year. In a subset of 32 patients, paired QCA showed mean in‐scaffold LLL of 0.18 ± 0.31 mm at 6‐month follow‐up. In a subset of 21 patients, OCT revealed 97.95 ± 3.69% strut coverage with mean scaffold area of 7.56 ± 1.79 mm 2 and no evidence of strut malapposition. Conclusions: The clinical and imaging outcomes of MeRes‐1 Extend trial demonstrated favorable safety and efficacy of MeRes100 sirolimus‐eluting BRS in patients with de novo coronary artery lesions.